SmartCardia announced today that it received FDA clearance for mobile outpatient cardiac telemetry (OCT/MCT) for its ECG ...

such as remote patient monitoring, digital consent forms, telemedicine, electronic clinical outcome assessments (eCOAs), ...

Masimo (NASDAQ: MASI) today announced that its management will ... clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from ...

After watching a pulse oximeter struggle with his father’s dark skin, @AmBeRnIgAm began a personal quest to confront racial ...

Professor Allan Lawrie discusses the future of personalised cardiovascular disease detection and monitoring and wearable ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

MAMO sees a 30.7% increase in non-GAAP operating income in Q3 2024. Healthcare segment revenues increase 11.5%, driving overall growth amid strategic shifts.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.